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Abstract: Periodontitis is an inflammatory disease with a bacterial etiology in a 
susceptible host. Given the bacterial etiology, a selective antimicrobial agent with 
minimal side effects could be a useful adjunct to traditional therapy. Amixicile is a novel 
antimicrobial that targets the pyruvate: ferredoxin oxidoreductase (PFOR) which is an 
enzyme that is critical for anaerobic bacterial metabolism. It has been found to have no 
effect on commensal, aerobic microbes and has little to no side-effects thus far in 
animal models. In this study, two nonhuman primates of the Macaca mulatta species 
with naturally occurring mild chronic periodontitis were studied before and after a two-
week course of systemic administration of amixicile and at 3- and 6-months post-
treatment. Periodontal charting including probing depths, clinical attachment levels, 
presence of bleeding on probing, and presence of plaque was recorded at each visit in 
addition to collecting saliva and subgingival plaque samples. The microbial composition 
of the plaque and saliva was evaluated based on 16s rDNA analysis. Both animals’ 
clinical conditions saw a reduction in probing depths and clinical inflammation. In the 





anaerobes, was seen with a concomitant increase in Streptococcus, Haemophilus, 
Gemella, and Escherichia, all aerobes, was observed. Subgingival plaque samples 
showed similar alterations in microbial composition. Reduction of Porphyromonas, 
Fusobacterium, Prevotella, Veillonella, and Alloprevotella, all anaerobes, was observed 
with concomitant increase of known aerobes. These changes generally take place 
immediately post-treatment but return to baseline levels by 6-months. Thus, it was 
concluded that due to its selectivity for anaerobic periodontal pathogens and lack of side 
effects, amixicile is a strong candidate as a viable antimicrobial option for the treatment 
of periodontal disease. 
 







Periodontitis is an inflammatory disease with a bacterial etiology in a susceptible 
host1. Given the bacterial etiology, antibiotics have been used regularly but judiciously 
in the treatment of aggressive and severe chronic periodontitis cases. Antibiotics such 
as amoxicillin, metronidazole, tetracycline, azithromycin, and clindamycin have been 
studied and found to be effective2. These antibiotics, however, are broad-spectrum, 
exerting their effects on both aerobic and anaerobic bacteria i.e. both commensal and 
pathogenic flora, and, if used, serve as an adjunctive therapy3. It has been well 
established that in health the microflora is dominated by aerobic species, especially 
Streptococcus sp., while periodontitis is characterized by a shift to pathogenic, 
anaerobic microorganisms4,5 (Figure 1). Thus, when a broad-spectrum antibiotic is 
used, it will eliminate the aerobic bacteria allowing for reinfection by the pathogenic 
anaerobic species, which enjoy the protection of biofilms in the forms of dental plaque 
and calculus. Without the competition of the commensal aerobic species the anaerobes 
can multiply in periodontal pockets which favor their proliferation. It is well established 
that these pathogenic, anaerobic bacteria are found in periodontal pockets and include 
such species as Porphyromonas gingivalis (P. gingivalis), Tannerella forsythia (T. 
forsythia), and Treponema denticola (T. denticola) which make up the so-called "red 
complex" while Campylobacter rectus (C. rectus), Fusobacterium nucleatum (F. 
nucleatum), Parvimonas micra (P. micra), and Prevotella intermedia (P. intermedia) 
comprise the “orange complex”6. In periodontally healthy sulci species such as 
Actinomyces naeslundii (A. naeslundii), Streptococcus oralis (S. oralis), Streptococcus 




Haemolysans), and Neisseria spp. are more abundant4. Finally, currently used 
antibiotics do not eradicate bacteria that are internalized by host cells and serve as a 
reservoir for re-infection. 
 
Figure 1. This figure is adapted from the findings of Löe, 1965 showing the shift in the oral microflora from health 
through gingivitis with the cessation of oral hygiene5. 
 Metronidazole is a semi-selective antibiotic that targets anaerobic species and 
has been used as an adjunct to mechanical therapy in the treatment of aggressive and 
refractory periodontitis7. It acts as a prodrug that is partially reduced inside of anaerobic 
bacteria and some protozoans, which makes it selective for these populations. Once it 
has been reduced into its active form, it disrupts bacterial nucleic acid synthesis8. 
Metronidazole is generally used in combination with Amoxicillin as a very broad-
spectrum approach based on reducing the overall bacterial load. When used in 
combination with Amoxicillin, significantly greater probing depth reduction and clinical 




Metronidazole was found to be effective in reducing the need for surgical therapy when 
given in conjunction with traditional mechanical therapy7. Its use has been limited, 
however, due to side effects including yeast infection, neuropathy, neurotoxicity, 
pancreatitis, encephalopathy, and sometimes-severe gastrointestinal effects which can 
lead to colitis if used repeatedly10. Thus, the need for a new antimicrobial agent that will 
specifically target periodontal anaerobes with minimal to no side effects is apparent. 
 Criticism of the use of antibiotics in addition to mechanical therapy for the 
treatment of periodontitis comes primarily due to unwanted side effects and contribution 
to bacterial resistance11. Metronidazole has a very low occurrence of acquired 
resistance due to its requirement to be taken into the cell and degraded into its active 
form inside of anaerobic cells7. Similar selectivity in a substitute drug would be an 
optimal characteristic. 
 Recently, the Hoffman laboratory at the University of Virginia, Department of 
Medicine, has developed amixicile as an anaerobe-specific antimicrobial with a novel 
mechanism to be used for the treatment of Clostridium difficile infections11. Amixicile is a 
derivative of nitazoxanide in which a 2-acetoxy group has been replaced with an 
aliphatic amine making the drug much more soluble as well as avoiding glucuronidation 
in the liver. Using a murine model, the Hoffman lab was able to show a high degree of 
specificity toward anaerobic gastrointestinal pathogens leaving commensal flora intact 
with no notable side effects. This drug’s novel mechanism targets a vitamin B1 
(thiamine pyrophosphate) cofactor involved in the pyruvate: ferredoxin oxidoreductase 
(PFOR) metabolism essential to anaerobic bacteria. This highly specific target allows 




bacterial resistance. Aerobic bacteria rely on pyruvate dehydrogenase (PDH) for 
metabolism and thus are unaffected by treatment with amixicile. Even when given at 
very high dosages that were well beyond the minimum inhibitory concentration (MIC) no 
adverse effects were observed in the mice11. 
 
Figure 2. Chemical structures of amixicile and its precursor nitazoxanide. 
 In addition to its effect on anaerobic bacteria, amixicile would seem to be a 
candidate for treating periodontal infection due to its ability to localize at sites of 
inflammation. This property was identified during studies on amixicile’s effect on C. 
difficile infections and the mechanism has to do with mucosal inflammation which 
causes local tissue destruction and serum leakage12. It is known that periodontal 
disease causes localized tissue breakdown as evidenced by pocket formation which is 
accompanied by an increase in gingival crevicular fluid which is an inflammatory 
exudate derived from serum13. It was shown that amixicile is highly soluble reaching 
high levels in serum thus it would be plausible that amixicile may localize to sites of 
periodontal inflammation and be delivered to the sulcus via gingival crevicular fluid11. 
 The next step in evaluating amixicile for potential periodontal therapy was to 
verify that it would be effective on oral pathogens and in the oral environment. As stated 




inflammation and dysbiosis than others. Given this fact, P. gingivalis, P. intermedia, F. 
nucleatum, and T. forsythia were evaluated via the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) and all were found to have genes encoding for the PFOR enzyme 
that has shown to be the target of amixicile. Known anaerobes, S. gordonii, and A. 
actinomycetemcomitans, were found only to have genes encoding for PDH and thus 
should be unaffected by amixicile. This was tested and confirmed using an in vitro 
model in which it was found that amixicile inhibited the growth of P. gingivalis, P. 
intermedia, F. nucleatum, and T. forsythia while it did not affect the growth of S. gordonii 
nor A. actinomycetemcomitans in a monoculture environment. These microbes were 
then combined into a multispecies culture that would represent the way they may live 
and interact within a biofilm and again it was found that amixicile inhibited the growth of 
P. gingivalis, P. intermedia, F. nucleatum, and T. forsythia, while it did not affect the 
growth of S. gordonii nor A. actinomycetemcomitans in a multi-species environment. 
The experiment was carried one step further with the addition of 10% saliva and 10% 
serum to the multi-species culture to continue to simulate an oral environment and the 
results continued to show that amixicile successfully and selectively targeted anaerobes 
in a simulated oral environment14. 
 Continuing in the pre-clinical investigation of amixicile’s potential application in 
treating periodontal disease, its efficacy in inhibiting Treponema denticola (T. denticola) 
was evaluated. It has been found that in a healthy periodontium oral treponemes only 
comprise about 1% of the sulcular microflora but in disease this proportion can reach 
40-50%15. Again, it was shown in vitro that amixicile was a potent inhibitor of T. 




shown to inhibit both bacterial motility as well as reducing the production of hydrogen 
sulfides which have been shown to induce apoptosis of cells of the human 
periodontium16. Progressing to an ex vivo model using a well-developed oral salivary 
microbiome derived from human subjects it was again shown that amixicile selectively 
inhibited anaerobic bacteria containing the PFOR enzyme and that aerobic bacteria 
were unaffected in a simulated oral environment representing a plaque biofilm17.  
Finally, an ex vivo periodontal microbiome derived from gingival pockets of 
patients with periodontal disease was used to determine amixicile’s efficacy in a 
naturally derived biofilm. The importance of this is underscored by the fact that there is 
a large diversity of bacterial strains in the periodontal microbiome, so it is essential to 
test strains derived from clinical samples from diseased sites. Again, it was found that 
amixicile was able to selectively inhibit anaerobes while sparing commensal aerobic 
flora which can help prevent reinfection18. 
Table 1. Genus and species of oral bacteria that rely on PFOR versus PDH for their metabolism of glucose. All 
microbes relying on PFOR should be susceptible to amixicile, while those utilizing PDH should not.  
PFOR Metabolism (Sensitive to 
Amixicile) 
PDH Metabolism 
P. gingivalis, P. intermedia, F. 
nucleatum, T. denticola, P. micra, and 
T. forsythia. Porphyromonas spp., 
Veillonella spp., Prevotella spp., 
Alloprevotella spp., and Fusobacterium 
spp. 
S. gordonii, S. oralis, C. rectus, and A. 
actinomycetemcomitans. Actinomyces spp. 
Streptococcus spp., Klebsiella spp., 
Neisseria spp., Lactobacillus spp., 
Haemophilus spp., Gemella spp., 





Figure 3. Representation of plaque biofilm showing early, middle, and late colonizers. Microbes are color-coded 
according to either PDH or PFOR metabolism.  
 The present study will move the examination of amixicile into an in vivo, 
preclinical animal model using the nonhuman primate (NHP), Macaca mulatta (M. 
mulatta). In choosing an appropriate model for the study the anatomical, clinical, and 
microbiological features of the animal should resemble the same features of a human 
subject as closely as possible. In a review of animal models for the study of 
periodontitis, the NHP model was found to be superior to other animals including 
porcine, canine, and rodent models (Table 1). The anatomy of oral structures and teeth 
of the NHP is found to be very similar to that of the human as well as the natural 
occurrence and formation of dental plaque and calculus. The clinical progression of 




The only drawbacks of a simian model that were noted were the expensive of acquiring 
and maintaining the animals as well as animal husbandry issues i.e. socialization and 
mental stimulation, etc.19. A review of non-human primate species found the M. mulatta 
to be similar to the human anatomy and disease progression with some differences. 
There are histologic similarities in the periodontal tissues as well as the changes in 
those tissues from health to disease including widened intercellular spaces, an increase 
in PMNs, an increase of inflammatory cells in the connective tissue, destruction of 
collagen and formation of deepened periodontal pocketing, and finally bone resorption, 
all of which are similarly observed in the human disease progression. The primary 
difference noted was a higher proportion of Actinomyces sp. in NHP in both healthy and 
diseased sites. Microbiologically, M. mulatta shows an increase in motile rods and 
spirochetes with increased inflammation. In established gingivitis lesions the proportion 
of anaerobes continues to increase as well as the overall bacterial counts. In 
experimentally-induced periodontitis an increase in P. gingivalis and P. intermedia was 
observed20. 
Table 2. Comparison of animal models available for periodontal research including their anatomical features, 
microbiological characteristics, and logistical considerations. 
Model Anatomy Microbiome Logistical 









Microbiota differs from 
that of the human. P. 
gingivalis and A. 
actinomycetemcomitans 
do not naturally occur. 
Small size makes 
procedures 
difficult and the 
amount of tissue 





Dog Oral structures 





differ from that 
of the human. 
Subgingival plaque 
consists of gram (-) 
anaerobic cocci and rods 
similar to humans 
including P. gingivalis 






space can be 
prohibitive. 










Naturally occurring P. 




















Very similar to human. 




Actinomyces spp., P. 
micra, F. nucleatum, and 







 A greater understanding of the subgingival microflora of the M. mulatta species 
was gained and correlated to health versus clinically apparent inflammation. Mild 
inflammation showed an increase in Haemophilus species (spp.), Actinomyces spp., P. 
micra, F. nucleatum, Eikenella corrodens (E. corrodens), and A. 




planing and a considerable increase in aerobes and simultaneous decrease in 
anaerobes was observed. The key difference in the NHP was again notably high A. 
actinomycetemcomitans in both healthy and diseased sites21. As sequencing 
technology improved the microflora of M. mulatta were more thoroughly evaluated and 
the findings were correlated to clinical parameters. From a global look at the microbes 
present it was found that 56% of the bacteria were identical to or had closely related 
human counterparts. Forty-eight species were unique to the macaque but all of these 
also had clearly and closely related human counterparts. Health associated microbes 
were found to be Streptococcus spp., Lactobacillus spp., and Gemella spp. Periodontal 
pathogens associated with clinical inflammation and bone loss were found to be P. 
gingivalis, T. forsythia, Filifactor alocis, P. micra, Treponema spp., Fusobacterium spp., 
and A. actinomycetemcomitans.  
It was determined that in the M. mulatta a 4mm probing depth (PD) along with 
clinical inflammation and bleeding on probing (BOP) is mild periodontitis. A PD of 5mm 
or greater with inflammation and BOP is considered moderate to severe periodontitis. 
All clinical features found in human periodontitis are present in the M. mulatta including 
increased probing depths and bone loss22. Bleeding on Probing (BOP) and its relevance 
to disease activity has been studied extensively. It has been reported that the presence 
of BOP can have a high false-positive for predicting periodontal breakdown but the 
negative predictive value was found to be 98%, meaning that an absence of bleeding is 
a reliable predictor of periodontal health23. Both visible inflammation (redness and 
edema) of the gingiva and BOP have been correlated histologically to an increase in 




tissue24,25. Given the value of these clinical findings, a modified Gingival Index (GI)26 
and BOP will be evaluated and correlated to the microbiological findings. 
This study will aim to expand upon the in vitro research previously completed by 
testing the hypothesis that amixicile will selectively inhibit anaerobic periodontal 
microbes that code for the PFOR enzyme in in vivo conditions in the Macaca mulatta. 
Microflora will be collected, and data recorded for probing depth (PD), clinical 
attachment level (CAL), gingival index (GI), plaque index (PI), presence or absence of 
calculus (C), and bleeding on probing (BOP) at baseline, immediately post-treatment 
and then at 3- and 6- months following a two-week treatment with amixicile. No other 







All animal procedures were performed according to the protocol approved by the 
Virginia Commonwealth University (VCU) Institutional Animal Care and Use 
Committees (IACUC) (Approval # AD10001255). Two male non-human rhesus 
primates, M. mulatta, were used in our study. Animal G’s dentition was healthy and free 
of caries or endodontic pathology with tooth #6 having previously treated non-surgical 
root canal therapy with an MF amalgam restoration. Animal T’s dentition was healthy 
and free of caries or endodontic pathology. The animals were housed at the VCU’s 
animal facility in extra-large enclosures. Both subjects were fed a diet of kibble (Monkey 
Chow, Purina) and fresh fruits and vegetables as well as foraging for dried seeds, dried 
fruits, and nuts daily. They were provided social and environmental enrichment through 
daily handling by animal technicians, visual contact with other animals, and other 
enrichment items (toys, videos, etc.). Animals enrolled in this study were systemically 
healthy. 
Clinical Examination and Sample Collection 
 Clinical periodontal examination was performed by a graduate resident 
specializing in periodontics (DL) under the supervision of a faculty periodontist (JGD). 
The animals were placed under general anesthesia by way of an injection of ketamine 
(10 mg/kg) followed by intubation and administration of 2% isoflurane at 2 L/min and 
100% oxygen at 1 L/min. The comprehensive periodontal examination was performed at 




Baseline exams were performed to determine the clinical and microbiological status of 
the animals. 
A complete set of clinical photographs was taken at each examination. The 
clinical photographs were used to assign a modified Gingival Index (GI)26 score to each 
sextant. The scoring was based on the following classification: GI 0 = pale pink to pink, 
knife-edge margin, positive architecture; GI 1 = slightly more reddish, slight marginal 
edema, clear exudate, no BOP; GI 2 = red to bluish-red, glazy, marginal edema, BOP 
apparent in the photograph; GI 3 = markedly red to bluish, edematous, 
BOP/spontaneous bleeding apparent in the photograph. Photographs were randomized 
and then each sextant was scored with a single value by three independent examiners 
(JGD, DL, EB). Scores of each examiner were averaged to come up with the GI of each 
sextant for the initial exam, immediately post-amixicile, 3 months post-treatment, and 6 
months post-treatment. 
Saliva samples were collected using five cotton swabs equally representing all 
areas of the mouth by swabbing the entire oral cavity including buccal and sublingual 
spaces. The cotton swabs with the sample were placed into microcentrifuge tubes 
containing 500 µl of phosphate-buffered saline (PBS, pH 7.2) and RNAlater solution 
(Invitrogen, Waltham, Massachusetts, USA). 
Gingival crevicular fluid (GCF) and microbiology samples were collected from the 
same sites to correlate the findings. Samples of GCF and subgingival plaque were 
taken from the following sites at baseline: #1D, 2D, 3D, 14D, 15D, 16D, 20D, 21D, 22D, 
27D, 28D, and 29D. Since no mechanical therapy was to be performed as part of the 




16M, 20M, 21M, 22M, 27M, 28M, 29M for all follow-up exams. For subgingival plaque 
collection a Nevi 2 periodontal scaler (SCNEVI29E2, Hu-Friedy, Chicago, Illinois, USA) 
was inserted to the base of the attachment and plaque was collected from the 
subgingival tooth structure and placed into microcentrifuge tubes containing 500 µl of 
phosphate-buffered saline (PBS, pH 7.2) and stored at -80oC. For GCF collection, a 
Periostrip paper (Periopaper Gingival Crevicular Fluid Collection Strip, Fisher Scientific 
International, Pittsburgh, Pennsylvania, USA) was inserted into the periodontal sulci of 
interest and left for 30 seconds or until completely visibly saturated. The samples were 
collected into microcentrifuge tubes containing 500 µl of phosphate-buffered saline 
(PBS, pH 7.2) and stored at -80oC. 
 





The clinical exam consisted of determination of 1. Probing depth (PD, distance in 
millimeters between the gingival margin and the base of the sulcus or pocket) and free 
gingival margin (FGM, distance in millimeters from the CEJ to the margin of the 
unattached gingiva) measured at four sites per tooth: mesiobuccal, buccal, distobuccal, 
and straight palatal or lingual; 2. Clinical attachment level (CAL) was calculated at each 
of the aforementioned sites using the formula CAL = PPD – FGM; 3. Presence or 
absence bleeding on probing (BOP, Bleeding on Probing); 4. Presence or absence of 
plaque (PI, Plaque Index); 5. Presence or absence of calculus. 
Baseline exams were performed to determine the periodontal and microbiological 
status of the animals. Following the initial exam, the animals were then left for 14 days 
without any intervention prior to the administration of amixicile. The animals were then 
treated with 40 mg/kg/day of amixicile divided into two doses, encased in marshmallow 
for 14 days. No changes were made to the animals’ diet and no oral hygiene measures 
were performed during the study period. Periodontal and microbiological exams as 
described above were performed immediately post-treatment, 3 months post-treatment, 





Figure 5. Experimental design showing the time frame of the exams and the sequence of events from plaque and 
saliva sample collection through analysis. 
Microbiological Analysis 
For assessment of the microbial content we analyzed both the saliva and 
subgingival plaque samples. Each sample for analysis was vigorously vortexed for 5 
min to break down any larger plaque complexes. DNA from each sample was extracted 
as described below. Plaque samples were processed individually while aliquots of saliva 
samples were pooled together prior to analysis. 
DNA Isolation. Collected plaque samples were suspended in 500 µl of RNAlater 
buffer (Fisher Scientific International, Pittsburgh, Pennsylvania, USA) and stored at -
80oC. Genomic DNA (gDNA) was isolated using 200 µl of the mixture with the 
PureLinkTM Microbiome DNA purification kit (Fisher Scientific International, Pittsburgh, 
Pennsylvania, USA) according to the manufacturer's instructions. Similarly, 200 µl of 




 Quantitative PCR (qPCR). The gDNA derived from the above microbiomes was 
used to quantify the presence of bacterial species in the various samples using a 7500 
Fast Real-time PCR machine (Fisher Scientific International, Pittsburgh, Pennsylvania, 
USA). Purified DNA (1 µL) and species-specific primers were added to Fast SYBR 
Green Mastermix (Fisher Scientific International, Pittsburgh, Pennsylvania, USA). 
Reactions were run using standard cycle conditions: 95°C for 20 sec (1 cycle); 95°C for 
3 sec, 60°C for 30 sec (40 cycles). The cycle threshold (Ct) data were collected and 
then converted to absolute fold change. 
 Metagenomic library generation and 16S rDNA Sequencing. Bacterial 16S 
ribosomal DNA (rDNA) amplification and library construction were done using the Zymo 
Research Quick-16STM NGS Library Prep Kit (Zymo Research, Irvine, California, USA). 
Low DNA input protocol was used in our study. Briefly, reactions were set up in 96 well 
“Targeted Plate” and the V3-V4 region of rRNA genes were amplified with the V3-V4 
primers and the Quick-16STM qPCR Premix. 25 cycles (and more, if required) at the 
profile: 95oC for 10 min, 95oC for 30 sec, 55oC for 30 sec, and 72oC for 3 min was used 
for amplification. Sufficient amplification was verified using the recommended final 
fluorescence (that was higher than the threshold fluorescence). Following cooling at 4oC 
the samples were transferred to collection plate and (PCR primers, dNTPs) were 
degraded with the enzymatic cleanup solution. Finally, the samples were transferred to 
a “barcoded plate” where index primers for multiplexing of the samples were added. The 
barcodes were added using 5 PCR cycles consisting of: 95oC for 10 min, 95oC for 30 
sec, 55oC for 30 sec, and 72oC for 3 min. Sufficient amplification during barcode 




then pooled in equimolar amounts and purified using the MagBead kit components 
(Zymo Research, Irvine, California, USA). The final 16S rDNA library was sequenced 
with the MiSeq Reagent Kit v3 (600-cycle) with pair end-setting and 2 x 250 bp on the 
Illumina MiSeq platform (Illumina, San Diego, California, USA). Sequencing was 
performed at the VCU Genomics and Microbiome Core, Richmond, Virginia, USA. 
Following sequencing, the samples were deconvoluted, barcodes were trimmed, and 
short sequences (<100bp) were removed. 
 Metagenomic Data Processing. The raw read sequences were analyzed with 
CLC Workbench software (version 12; Qiagen, Venlo, Netherlands) equipped with the 
Microbial Genomics Module plugin (version 2.0; Qiagen, Venlo, Netherlands). The 
paired-end reads were merged into one high-quality representative by settings of CLC 
Workbench (mismatch cost = 1, minimum score = 25, gap cost = 4, maximum unaligned 
end mismatches = 5). The parameter settings for the quality trimming were as follows: 
trim using quality scores, limit = 0.05; trim ambiguous nucleotides, maximum number of 
ambiguities = 2. Operational taxonomic unit (OTU) clustering and taxonomic assignment 
were carried out with the reference sequences from the Human Oral Microbiome 
Database (HOMD, Cambridge, Massachusetts, USA, 16S rRNA gene reference 
sequence [16S rRNA refSeq] Version 15.2) at a level of similarity of 97% of OTU.  
 Bioinformatics Analysis. Data were analyzed using the bioinformatics 
workflows available through CLC Genomics Workbench with the CLC Microbial 




Availability of Data. High throughput sequencing data were deposited to NCBI’s 
Sequence Read Archive (SRA) with the accession number SUBXXXX (submission 
pending). 
Due to the limited sample size and nature of this pilot study, statistical data 
analysis will be primarily descriptive in nature with the intent of providing information to 






Amixicile reduces clinical periodontal inflammation. The periodontal 
examination of both animals revealed mild periodontitis at several sites (Tables 5A, 
5B)22. We examined twelve teeth per animal for bleeding on probing (BOP), pocket 
depth (PD), and microbiological samples of subgingival plaque and saliva. Three sites 
(MB, B, DB) were examined/tooth thus making up thirty-six sites per animal examined. 
At the baseline exam for Animal G there were 3 teeth with three sites that had PD of 
4mm, which correspond to mild periodontitis for NHP, and seven sites with PD of 3mm 
22. For the second animal, Animal T, there were two teeth, each with one site with PD of 
4mm and eleven sites with PD of 3mm. We thus concluded that the clinical 
characteristics point to an acceptable level of periodontitis to be used in our study.  
A modified Gingival Index (GI) was evaluated in the two specimens examined at 
four timepoints during the study period. Agreement on the modified GI between pairs of 
independent raters ranged from 0.56 to 0.69 which is considered moderate to 
substantial agreement. This amounts to agreement in scores for 71%-79% of images 
viewed. Results are given in Table 3. 
Table 3. Agreement in Gingival Index when Assessed from Clinical Photos by 3 Independent Raters 
 
 




DJL 0.66 0.51-0.81 Substantial 77% 
JGD-
EEB 0.56 0.40-0.73 Moderate 71% 
JGD-






Figure 6. Gingival Index for Animal G and Animal T by Sextant Across Visits 
As shown in Figure 6 above, GI was summarized by sextant (Upper Left, Upper 
Right, Lower Left, Lower Right). The average GI was calculated by averaging across 
the three raters and across all pictures as detailed in the Methods. The trends for GI by 
monkey and sextant are given in Figure 6. Data for the GI of Animal G for the Upper 
Left sextant was not available. GI was relatively steady on Upper and Lower Left. Upper 
Right initially decreased for Animal G and then increased steadily from 3-month and 6-
month examinations. Animal T increased slightly from Initial to 3-month examinations 
and then decreased by the 6-month exam. The Lower Right demonstrated a decrease 
from the Initial exam to Post-treatment and then increased at the 3-month exam. 
Between the 3-month examination and the 6-month examination, Animal T remained 




Clinical findings across the study visits are summarized in Table 4. Further 
statistical analyses were not performed due to the limited number of animals. Average 
probing depth for Animal G increased from initial to both the post-treatment and 3-
month examination and then decreased by the 6-month follow-up. Animal T saw an 
initial decrease at the post-treatment exam followed by an increase at the 3-month visit 
and a decrease at 6-months. Both monkeys were at or below their initial average 
probing depth by the 6-month examination (Animal G: 2.00 vs 1.99; Animal T: 1.93 vs 
1.73; Fig. 6A). In terms of bleeding sites (Fig. 4B), both monkeys saw an initial increase 
from the initial examination to the post-treatment followed by a substantial improvement 
back to baseline at the 3-month follow-up. By the 6-month follow-up, Animal G had an 
additional decrease in bleeding sites, but Animal T saw a slight increase. The number of 
plaque sites increased for both monkeys progressively from initial examination through 
the 6-month follow-up (Fig. 4C). Both began with 0 plaque sites at the initial examination 














Table 4. Summary of Clinical Findings by Visit 
 
In Animal G, twelve of the thirty-six sites (33.3%) exhibited BOP at baseline. 
Similarly, in Animal T, there were four sites with BOP out of the thirty-six tested (11.1%). 
Immediately following amixicile treatment the number of sites with BOP remained 
similar to baseline. Three months post-treatment there were no sites with PD of 4mm in 
either animal. There were fourteen sites in animal G and eleven sites in animal T with 
PD of 3mm. Significantly, all the sites that previously were 4mm were reduced to 3mm 
or less at 3 months post-treatment. Bleeding on probing (BOP) remained similar to 
baseline at the 3-month post-treatment exam. At the final exam there were still no sites 
measuring 4mm and only eleven sites with PD of 3mm in each of the animals. A 
significant reduction in BOP in animal G was noted where we detected four sites, or 
11.1%. Animal T experienced a rebound in BOP by the 6-month exam having eight sites 
(22.2%) exhibiting BOP. All of the above shows that a two-week treatment with amixicile 
  Gizmo 
  Initial Post 3 Months 6 Months 
Average Probing 
Depth 2.00 2.09 2.14 1.99 
Number of Bleeding 
Sites 12 29 17 4 
Number of Plaque 
Sites 0 51 80 96 
Gingival Index 
UL UR UL UR UL UR UL UR 
2.67 2.17 2.08 1.5 2.17 2.17 2 2.5 
LL LR LL LR LL LR LL LR 
 -- 0.83 0.067 0 1 0.5 0.83 1.17 
  Tango 
  Initial Post 3 Months 6 Months 
Average Probing 
Depth 1.93 1.78 1.91 1.73 
Number of Bleeding 
Sites 4 23 3 9 
Number of Plaque 
Sites 0 47 84 95 
Gingival Index 
UL UR UL UR UL UR UL UR 
1 1 0.89 0.33 0.83 1 1.4 0.83 
LL LR LL LR LL LR LL LR 





resulted in improvement in BOP in Animal G from 33.3% to 11.1% (Fig. 7) and stability 
of PD in Animal G and a reduction in PD in Animal T from 1.93mm at baseline to 
1.73mm at the 6-month exam (Table 4, Fig. 8) all while both animals experienced a 
dramatic increase of detectable plaque biofilm (Animal G – 51 to 96 sites; Animal T – 47 
to 95 sites)(Fig. 9).  
 






Figure 8. Average Probing Depth for Animal G and Animal T Across Visits 
 




 A more focused examination of the effect of amixicile in Animal G shows teeth 
that had PD sites of 4mm at baseline included teeth #14, 15, and 16, all of which had 
PD of 3mm or less at 6 months post-treatment. At these teeth, BOP decreased from 
three sites to one site at three months post-treatment in animal G. That improvement 
was maintained through the six-month post-treatment exam. Similarly, in animal T at 
teeth #14, 15, and 16, sites with 4mm PD were reduced from two to zero from baseline 
through 6-months post-treatment. At these teeth, BOP was decreased to only one site 
at 3-months post-treatment, but Animal T experienced a rebound between 3 and 6 
months ending with three sites with BOP.  
Table 5. Clinical characteristics of Animal G at baseline (-B), Post-amixicile (-P), 3-months post-treatment (-3), and 6-
months post-treatment (-6). Clinical characteristics assessed: PD – pocket depth (shown in mm), BOP – bleeding on 





























Table 6. Clinical characteristics of Animal T at baseline (-B), Post-amixicile (-P), 3-months post-treatment (-3), and 6-
months post-treatment (-6). Clinical characteristics assessed: PD – pocket depth (shown in mm), BOP – bleeding on 
probing (B – bleeding, N – no bleeding) 
 
Amixicile reduces the abundance of anaerobic bacteria within the salivary 
microbiome. Saliva from all sites has been collected and pooled prior to analysis. 
Aliquots of saliva collected during baseline and follow up periodontal exams have been 
used to isolate total DNA. The DNA was used for 16S rDNA sequencing and data was 
analyzed at the genus and species level (Fig. 10-13). Analysis of the data derived from 
Animal G at the genus level revealed that at baseline the most dominant were bacteria 
belonging to the Streptococcus genus followed by Haemophilus, Porphyromonas, 
Gemella, and Fusobacterium genera (Fig. 10). In the second animal, Animal T, bacteria 
belonging to the Neisseria genus were the most abundant while bacteria belonging to 
the genera of Porphyromonas, Streptococcus, and Gemella were also abundant (Fig. 
12). Having large proportions of anaerobic bacteria, specifically bacteria belonging to 
Porphyromonas and Fusobacterium, justified the use of this model for testing of 
amixicile’s efficacy. Following treatment with amixicile, reduction in anaerobic bacteria 
with a concomitant increase in aerotolerant ones was observed. Specifically, a reduction 
in bacteria belonging to the genera Porphyromonas, Fusobacterium, and Alloprevotella, 
all anaerobes, was seen in Animal G. At the same time, an increase in Haemophilus, 
Gemella, and Escherichia, all aerobes, was detected (Fig. 10). At the species level, 
Animal G showed a dramatic reduction of F. nucleatum immediately post-treatment with 
some rebound through 6-months but never reaching pre-treatment levels (Fig. 11). 
Streptococcus remained at similar levels to the pre-treatment phase. In the second 
animal, Animal T, we also observed a reduction in bacteria belonging to Porphyromonas 
(Fig. 12). However, a reduction in Neisseria, an obligate aerobe, was also observed. An 
increase in levels of aerotolerant bacteria belonging to the Streptococcus, Haemophilus, 
and Gemella genera was observed (Fig. 12). These results demonstrate that amixicile 
was effective in reducing the levels of anaerobic bacteria present in the salivary 




Figure 10. Amixicile reduces the abundance of anaerobic bacteria within the salivary microbiome. Animal G – Genus 
level analysis. 
 
















Amixicile reduces the abundance of anaerobic bacteria in gingival pockets. 
Four sites of subgingival plaque biofilm from Animal G (#3,14,16,22) and four sites from 
Animal T (#3,14,15,16) were successfully surveyed for the composition of the oral 
microbiome at baseline and following amixicile treatment (Fig. 14-17). Survey of the G3 
(Animal G, tooth #3) site at the genus level in Animal G indicated that at baseline 
Porphyromonas and Fusobacterium were highly dominant. Other abundant bacteria 
included Leptotrichia, Prevotella, and Streptococcus. Following amixicile treatment a 
significant reduction in both Porphyromonas and Fusobacterium levels was observed. 
This corresponded to an increase in levels of Leptotrichia and Prevotella (Fig. 14). 
Analysis of the G14 site has shown that at baseline Escherichia, Prevotella and 
Streptococcus were highly abundant genera (Fig. 15). Following amixicile treatment 
levels of Escherichia and Prevotella were reduced while those of Leptotrichia and 
Fusobacterium were increased. Baseline abundance of the G16 site has shown high 
levels of Escherichia, Veillonella, Streptococcus, Leptotrichia, Prevotella, and 
Fusobacterium (Fig. 16). Following treatment, the abundance of Veillonella, 
Streptococcus, Leptotrichia, Prevotella, and Fusobacterium were reduced while that of 
Escherichia, Actinomyces, and Aggregatibacter was elevated. The fourth site of Animal 
G, G22, has shown a high abundance of Escherichia, Porphyromonas, Prevotella, 
Fusobacterium, and Alloprevotella. Following antibiotic treatment, the levels of 
Porphyromonas, Fusobacterium, and Alloprevotella were reduced with an increase in 
Leptotrichia, Selenomonas, Prevotella, and Actinomyces. Interestingly, levels of 
Streptococcus were also reduced (Fig. 17). Overall, in Animal G we observed a 




ones. There was significant variation in the microbial composition of the baseline 
microbiome as well as post-treatment.  
 
Figure 14. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 
analysis – Site G3. 
Figure 15. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 





Figure 16. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 
analysis – Site G16. 
 
Figure 17. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 




Analysis of the subgingival microbiomes of Animal T, both at baseline and post-
treatment has shown a similar trend in that levels of anaerobic bacteria were reduced in 
favor of the aerobic ones (Fig. 18-21). Specifically, the abundant genera of T3 (Animal 
T, tooth #3) were Escherichia, Streptococcus, Porphyromonas, and Prevotella. 
Following amixicile treatment the abundance of Prevotella was significantly reduced. 
Increased levels of Escherichia, Streptococcus, Aggregatibacter, and Peptidiphaga 
were observed (Fig. 18). At the second site of the Animal T, T14, Streptococcus, 
Porphyromonas, and Fusobacterium were the dominant bacterial genera. After amixicile 
treatment, the levels of Porphyromonas, Fusobacterium, and Streptococcus were 
significantly reduced. That corresponded to an increase in levels of Escherichia, 
Aggregatibacter, and Peptidiphaga (Fig. 19). The T15 site at baseline was abundant in 
Escherichia, Streptococcus, Porphyromonas, and Haemophilus. Following amixicile 
treatment the levels of Porphyromonas, Streptococcus, Haemophilus, and 
Fusobacterium were significantly reduced with an increase in the levels of Leptotrichia 
and Bacteroides (Fig. 20). The final site analyzed for microbiome composition, T16, had 
high levels of Escherichia at baseline that were reduced with a concomitant increase in 
levels of Streptococcus (Fig. 21). Thus, similar to Animal G, we observed high variability 
between the microbial composition of samples derived from different sites. However, the 
common theme from all the treated sites was a reduction in the abundance of anaerobic 
bacteria and an increase in levels of aerotolerant ones. In conclusion, amixicile 
effectively reduced levels of subgingival anaerobic bacteria in the treated samples while 





Figure 18. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 
analysis – Site T3.  
 
Figure 19. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 





Figure 20. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 
analysis – Site T15. 
 
 
Figure 21. Amixicile reduces the abundance of anaerobic bacteria within the subgingival microbiome, site-specific 






The effect of amixicile on the oral microbiome is reversed after several 
months post-treatment. We followed the animals’ microbiome changes up to six 
months post-treatment. Between 1- and 6- months post-treatment the salivary 
microbiome of Animal G had an increase in the abundance in Porphyromonas, 
Fusobacterium, and Leptotrichia while reduction in Haemophilus, Streptococcus, and 
Gemella was observed. The composition resembled the baseline microbiome, however, 
higher levels of Leptotrichia were seen. In Animal T, the salivary microbiome had higher 
levels of Haemophilus and Fusobacterium at longer post-treatment intervals. In the 
subgingival microbiome, an increase in the proportion of anaerobic bacteria was also 
observed after longer timeframes.   
 Correlation between microbiome and clinical characteristics. Significant 
clinical improvement as determined by PD, BOP, and GI was observed at three months 
post-treatment and continued into the sixth month. The clinical improvements were 
delayed with respect to the onset of the reduction of anaerobic bacteria in the 
microbiome. At six months, despite some reversal of the abundance of anaerobic 







The work presented here shows that the use of a 14-day treatment of amixicile at 
40mg/kg/day is effective in reducing the symptoms of periodontal disease as manifested 
by probing depths (PD) and bleeding on probing (BOP). While the average PD 
remained relatively steady, all sites measuring 4mm (mild periodontitis in an NHP 
model) were reduced to 3mm or less by 3-months post-treatment, and this reduction 
was maintained through the endpoint of the study at 6 months. Similarly, reduction in 
gingival index (GI) was more notable at specific sites (Photo 1, A-C), which were not 
adequately captured in the average scores. Interestingly, bleeding on probing (BOP) 
increased immediately following the 14-day course of amixicile but then decreased 
dramatically at 3- and 6-months follow-up. This does not readily correlate to the GI 
scores given each animal at the designated timeframes. A striking observation is that 
while all of these clinical indices were either decreasing or remaining stable the sites 
with plaque were steadily and dramatically increasing (Fig. 6C). A possible explanation 
may be that although there is an increase in the number of microbes, the balance could 
be shifted to a plaque rich in commensal, aerobic bacteria due to amixicile’s selective 
targeting of the anaerobic periodontal pathogens. Without microbes belonging to the 
more virulent periodontal complexes described above there may be no inflammatory 






It is noteworthy that we also see the conversion of the composition of the salivary 
and sulcular microbiomes from one prevalent in anaerobic bacteria to one with reduced 
levels of anaerobes and increased proportions of aerotolerant microorganisms (Fig. 10-
21). In the saliva samples a reduction in Porphyromonas, Fusobacterium, and 
Alloprevotella, all anaerobes, was seen with a concomitant increase in Streptococcus, 
Haemophilus, Gemella, and Escherichia, all aerobes, was observed. Subgingival plaque 
samples showed similar alterations in microbial composition. Reduction of 
Porphyromonas, Fusobacterium, Prevotella, Veillonella, and Alloprevotella, all 
anaerobes, was observed with concomitant increase of known aerobes. These changes 
generally take place immediately post-treatment but return to baseline levels by 6-
months. 
There was a great degree of variability in microbial composition between 
individual sites which would be expected but makes comparison difficult. Microbial 
composition likely varies based on the depth of sulcus as well as environmental factors 




Animal T, site #16 at baseline is noteworthy (Fig. 21). This site had very little biofilm and 
was periodontally healthy at the initial exam. With such a small amount of biomass the 
DNA had to amplified many times to yield any data. This means that only microbes 
present in high abundance would be represented in the data and that it is uncertain 
which others may be present at low abundance. As the biofilm accumulated a more 
diverse flora is noted at the 6-month exam. 
When all the above data is taken together it seems that the microbiological 
effects of amixicile precede the clinical benefits. Although the microbiome tends to 
rebound between 3- and 6-months the clinical improvements persisted through the 6-
month exam. 
 Limitations to our study include a small sample size of only two non-human 
primates as the expense of acquiring and maintaining these animals is very great. 
Given that only two subjects were available for study both animals received the 
treatment so there was no control in our study. The animals also only exhibited mild 
periodontitis at worst in a small number of sites. Another limitation is that we were 
unable to measure the concentration of amixicile or any inflammatory markers in the 
GCF or serum so while the microbiological data would support its action it can’t be 
determined how well it was able to localize to the gingival sulcus. In our study V3-V4 
primers were used which allow for broader phylogenetic coverage that V1-V2 primers. 
This is both an advantage and a disadvantage as these primers target 16S rDNA, but 
different strains of microbes cannot be distinguished using this method. 
 The microbiological findings support the hypothesis that amixicile reduces the 




periodontal pathogens. These findings coupled with a reduction of clinical periodontal 
inflammation suggest that further study of amixicile for the treatment of periodontitis is 
warranted. Future studies should have a larger sample size and should include a 
negative control. Ideally, subjects would have more severe forms of periodontitis, and 
other antibiotics, possibly broad-spectrum, could be used for comparison or potentially 
in conjunction with amixicile. 
 The clinical implications of this study show great promise in amixicile as a novel 
antimicrobial for the treatment of periodontal disease. If amixicile continues to be found 
successful at selectively targeting periodontal pathogens with little to no side effects it 
may not only replace current antimicrobial options, such as the combination of 
Amoxicillin and Metronidazole, but it may make its use more routine for the treatment of 
periodontitis. In our study a 14-day course caused a significant reduction in pathogenic 
bacteria with a rebound of the microbes occurring between 3-6 months. With no side 
effects it may be possible to prescribe a 14-day course of amixicile once every 3-6 






In conclusion, amixicile seems to be a strong candidate as a viable antimicrobial 
option for the treatment of periodontal disease. It selectively inhibits known anaerobic 
periodontal pathogens including Porphyromonas spp., Fusobacterium spp., and 
Prevotella spp. causing a reduction in clinical periodontal symptoms for a period of up to 
six months. Further research at a larger scale is needed to bring the drug closer to the 
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